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Background: It is unclear why cystic ﬁbrosis (CF) survival has improved. We wished to quantify increases in CF median age of death in the
context of general population survival improvement.
Method: Death registration data analysis (US, England & Wales (E&W)—1972–2009).
Results: CF median age of death is higher in US than E&W and greater for males, opposite to that of death from all causes. CF median age of death
has increased by 0.543 life years per year (E&W, US combined (95% conﬁdence interval 0.506, 0.582)). The difference in median age at death
between those dying from all causes and CF decreased in both territories. CF median age of death for males is greater than for females in both
territories. This gap has not narrowed.
Conclusion: The median age of death of people with CF is improving more rapidly than that of the general population in US and E&W.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Survival; Mortality; Healthcare1. Introduction
Cystic fibrosis (CF) is the commonest autosomal recessive
condition among Caucasians and affects over 9000 people in the
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http://dx.doi.org/10.1016/j.jcf.2013.12.002[3]. Those affected suffer from the direct results of mutations in the
CFTR gene, causing CFTR dysfunction. This leads to increased
viscosity of their secretions leading, in many cases, to recurrent
lung infections, pancreatic insufficiency and diabetes mellitus.
These factors are associated with a reduced life expectancy. In
successive cohorts, survival, lung function and BMI have all been
demonstrated to improve over the last twenty years [2,4,5]. The
median life expectancy for a child born in the UK in the year 2000
was estimated to be greater than 50 years [4].
Although recent decades have seen a great improvement in
survival of individuals with CF, the explanation for this
improvement is not clear. Instead of observing a step-wise
change associated with each new intervention, a continuous
increase in the age at death over time is evident [4].
As factors responsible for influencing survival in CF are
intricately linked to survival in the general population, we
wished to explore the effect of the advances in CF care byby Elsevier B.V. All rights reserved.
Table 1
Numbers of deaths recorded for general population and cystic fibrosis (CF)
stratified by territory and sex. US data 1979–2009; England & Wales data
1972–2009.
England & Wales US Total
General population
Males 10414879 33000866 43415745
Females 10857458 31665675 42523133
Total 21272337 64666541 85938878
CF
Males 2247 6556 8803
Females 2375 6683 9058
Total 4622 13239 17861
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with CF in excess of that observed in the general population.
2. Method
Mortality data for each year by cause of death (all-cause and
CF deaths) and sex were retrieved from the Office of National
Statistics for England & Wales (E&W) (1968–2009) and
Centre of Disease Control (CDC: WONDER) for United States
(1979–2009). For the England & Wales data, over the age of
1 year data are available in 4-year bands whereas the US data
above the age of 1 is grouped in 4-year age bands until the age
of 25 years and subsequently the bands consist of 10-year age
bands. Median age at death was interpolated for data from each
country for all-cause mortality and CF mortality by sex. Data
use has been restricted to 1972 onward as prior to this date the
CF median age of death in England & Wales was less than one
year of age and so interpolation of a median age of death was
not possible. Median age of death has been used in this study
instead of survival as the latter, in estimating the survival
chances of individuals, relies upon a cohort methodology which
in this case would be unfeasible as it would involve retrieving
death certificates of millions of people.
Data were imported into StataSE 12 (StataCorp LP). The
absolute difference between and within groups (cause of death,
sex and country) over time was calculated. By constructing a
linear regression model of the differences between median age
of death for all-causes and CF, it is possible to determine gains
made for those with CF against a background of increasing life
expectancy for the general population.
Sensitivity analyses were performed using datasets covering
reduced timespans (1984–2004), to ensure that the trends
observed were consistent across the dataset and not dispropor-
tionately driven by a single year.
A subgroup of those that died in childhood between the ages
1 to 19 years in England & Wales was used to determine trends
in childhood annual age of death compared to other causes of
childhood mortality. A linear regression model of the difference
between childhood all-cause and CF mortality was constructed
to examine trends over time.
Ethical approval was not required.
3. Results
The death registration data detailed almost 86 million deaths
for the two territories combined, of which 17,861 entries were
for those who died with CF (Table 1).
3.1. Age of death from all causes in England&Wales is greater than
that in the US and age of death of women is greater than that of men
Fig. 1 illustrates the trend of continual improvement in the
age at death for all-cause mortality over time, increasing by
0.202 life years per year (95% confidence interval 0.135, 0.270)
for England & Wales and by 0.165 life years per year (95%
confidence interval 0.064, 0.266) for USA combined from
1972–2009. It is also clear that age at death in England &Wales for all-cause mortality is consistently higher than that in
the US. There is also a persisting sex difference favouring a
greater female age at death compared to males in both England
& Wales and the US.
3.2. Age of death from CF is greater in the US compared to the
UK and the age of death of men is greater than that of women
in both countries
Increasing median age of death from CF is demonstrated over
time in both countries as a group increasing by 0.543 life years
per year (95% confidence interval 0.506, 0.582). Median age at
death with a diagnosis of CF is greater in the US than in England
& Wales for all years data were available. In 2009, the median
age of death in the USA was 23.449 (Interquartile range 16.379,
27.603) and in England & Wales it was 22.125 (IQR—16.602,
31.992).
Similar to death from all causes, a sex difference is also
evident in the CF series however, in this instance favouring a
greater age at death for males in both countries (p N 0.0001)
(Fig. 1).
3.3. Improvements in the age of death from CF exceed that of
the improvement observed for the general population in the US
The absolute difference in the annual age of death from CF in
the USA compared to all-cause mortality from 1979 to 2009
decreased from 52.34 to 44.11 years for males (p b 0.001) and
from 61.22 to 53.2 years for females (p b 0.001). This represents a
2.86 and 2.77 fold improvement in age at death for CF compared to
all-cause mortality (males and females respectively). The reduction
in the difference between age at death between CF and all causes
for males equates to 0.276 person years per year (95% confidence
interval −0.336, −0.217) and for females 0.268 person years per
year (95% confidence interval −0.312, −0.224) (Table 2).
3.4. Improvements in the age of death from CF exceed that of
the improvement observed for the general population in
England & Wales
Over the same time period for which data is available in the
US (1979–2009) the absolute difference in the annual age of
death from CF in England and Wales compared to all causes
Fig. 1. Median age of death in England & Wales and the US for CF and all-cause mortality with milestones in care [29,30].
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to 59.04 for females (p b 0.001). This represents a 2.35 and
2.62 fold improvement in age at death for CF (vs. the general
population) in England & Wales over the period for which we
have US data, and a 3.12 and 2.82 fold improvement over the
whole time period for which we have data for England &
Wales (males and females respectively). The reduction in the
difference between annual age of death of CF and all causes
equates to 0.365 person years per year (95% confidence
interval −0.412, −0.319) for males and 0.367 person years perTable 2
Regression model of the difference in annual age of death (rate of change in life
years per year) observed between all-causes and CF in England and Wales
(E&W) and USA.
Negative values indicate a narrowing of the difference between the groups
under test.
Comparison Difference in annual
age of death
(life years per year)
95% confidence
interval
p-Value
CF
US vs E&W males −0.095 −0.158 −0.032 0.005
US vs E&W females −0.059 −0.126 0.008 0.083
E&W
CF males vs. females 0.018 −0.034 0.069 0.494
CF vs all cause males −0.365 −0.412 −0.319 b0.001
CF vs all cause
females
−0.367 −0.417 −0.317 b0.001
USA
CF males vs. females 0.013 −0.043 0.070 0.628
CF vs all cause males −0.276 −0.336 −0.217 b0.001
CF vs all cause
females
−0.268 −0.312 −0.224 b0.001year (95% confidence interval −0.417, −0.317) for females
(Table 2).
3.5. The differences in age of death from CF in England &
Wales and the US is narrowing
The difference in annual age of death between the two
countries for both sexes appears to be reducing over time,
although this only reaches statistical significance for males. The
difference between the US and England & Wales for males is
reducing at a rate of 0.095 person years per year (p = 0.005) and
for females a rate of 0.059 person years per year (p = 0.083)
(Table 2).
3.6. The sex difference in age of death from CF in England &
Wales and the US appears to be static
In the context of improvements in CF annual age of death and a
reduction in the differences between countries over time, the sex
difference in age at death however persists. There is no significant
reduction in the difference betweenmales and females observed in
either England & Wales (0.018 person years per year, p = 0.494)
or the US (0.013 person years per year, p = 0.628).
These observations were not qualitatively changed using
sensitivity analyses of varying time periods.
3.7. Stratified childhood analysis
Similar patterns of improvement are observed when limiting
the analysis to those who do not survive childhood (ages
1–19 years) in England & Wales. (Fig. 2). While the
differences in age at death between CF and all causes for
males and females have not only reduced but also improved
beyond that seen for children dying of other causes, the
413M.N. Hurley et al. / Journal of Cystic Fibrosis 13 (2014) 410–415differences between males and females are unchanged (p =
0.205)
4. Discussion
We aimed to quantify the improvement in annual age of death
in CF by comparing this improvement with that observed for the
general population's all-cause mortality in England &Wales and
the US. We have documented a significant improvement in
annual age of death for those with CF in excess of that observed
for all-cause mortality in both countries. While annual age of
death in the general population is greater in England & Wales
compared to the US, CF annual age of death appears to be greater
in the US, although this difference appears to be narrowing.
There remains evidence of a sex-specific disparity favouring
female annual age of death in the general population and male
annual age of death in those with CF. In contrast to differences
between country and CF/all-cause mortality, the sex difference
does not appear to be reducing over time.
This is the first study to quantify improvements in annual age
of death of CF in relation to all-cause mortality. While the deaths
from CF are nested in those of the general population(s), the
percentage is so small (UK for 2009—CF/all deaths—;0.02%)
that the CF death rate does not significantly contribute to that
from all causes.
It has previously been established that sex combined mortality
rates in the US are higher than those in the UK, and using gross
domestic product health expenditure (GDPHE) the US has been
less efficient and effective in reducing mortality compared to the
UK [6]. This may explain the survival advantage of the general
population in England & Wales that we observed, however it is
unclear why those with CF may have an improved survival in the
US compared to those in England & Wales. A similar survival
advantage favouring the US had previously been observed in theFig. 2. Linear regression model of differences betweenNetherlands, although in later cohorts (1990–1994) this had
disappeared [7].
CF-related survival differences between countries are difficult
to explain and have been variably ascribed to differences in rates
of care in specialised centres [7] (with centralised care said to
confer an advantage [8]), distribution of CF genotypes [9],
antibiotic regimens to treat or prevent infection and variations in
nutrition and environmental exposure [10]. Countries also vary in
rates of diagnosis [11] and it is also clear that the prevalence of
CF has reduced since the introduction of newborn screening [12],
the implementation of which has varied between countries.
In terms of survival advantage of the general population,
social determinants of health appear to be overriding [13]. It is
becoming increasingly understood that specifically for CF as
well, general factors including household income [14], socioeco-
nomic status [15], body mass index [16,17] and complications of
CF that effect the general population to some degree such as
diabetes [18] are predictive of outcome. It is possible that the
significantly increased rate of improvement in median age of
death of those with CF is because those with CF are more
sensitive to these societal factors that include standards of living.
While the influence of sex has been questioned[19], we
continue to document a reduced median age of death for women
with CF. Women with CF are more likely to be underweight than
their male counterparts [20] and poor nutrition is linked to poor
prognosis[21]. Furthermore, sex may be associated with more
intractable pulmonary infection. Oestrogen induces the mucoid
form of Pseudomonas aeruginosa (a phenotype associated with
poor prognosis [22]), and more mucoid P. aeruginosa is isolated
from women who experience more pulmonary exacerbations
[23].
This study has used ‘current survival’ to describe trends in
estimated survival over time. While this method cannot describe
trends in terms of birth cohort, and so cannot be predictive of anCF and all-cause childhood (1–19 years) mortality.
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unfeasible as this would involve retrieving death certificates of
millions of people. The limitations of using current survival
however are dwarfed by the strengths of this approach in that we
have been able to describe relational trends in survival for such a
substantial number of people over a considerable time period.
Patient group specific registries are a relatively recent
phenomenon and so there may be a significant lag before
sufficient numbers contribute to a survival analysis for future
extrapolation to be meaningful. In the meantime, death registry
data affords us a means to examine trends in causes of death
within a population. Death registry data has the advantage of
capturing a vast proportion of deaths, but there may be
diagnosis-related biases introduced in that historically deaths due
to CF may be overlooked, especially if the cause of death was
unrelated to cystic fibrosis, e.g. road traffic collisions. This could
conceivably be most marked in those diagnosed with CF in
adulthood who may have milder phenotypic presentations of CF.
Differences between the US and UK in the coding of death
certificates, particularly with regard to cystic fibrosis may
introduce bias, for example it may be that male adults investigated
for infertility and found to have congenital bilateral absence of the
vas deferens (CBAVD) are differentially classed as having cystic
fibrosis [24]. The effect of these cases on our study is likely to be
very small as are the numbers of cases involved.
It is well recognised that registry data are not entirely
representative of the population under study and rely on patient
consent, care in a CF centre and accurate reporting to the registry.
In one study only 45.9% of patients who died over the age of
45 years in a 14 year time period were reported by the CFF
Registry [25]. Our dataset similarly suffers by the risk of
misreporting, namely that should a person with CF die of another
cause other than CF, then this may be coded by the primary cause
of death and not CF. In addition, we have used the median age of
death which may mask subtle effects in the distribution of the age
of death—for example if changes at one end of the spectrum
(such as the introduction of a new medication) were offset by
contrasting changes at the other (an increase in death rate). The
likelihood of this occurring however is very small, but important
to acknowledge.
Previously, while it has been clear that CF survival has
improved, the cause of that improvement was unclear, especially
in the absence of treatment aimed at ameliorating the molecular
defect. It may be suggested however that, as the survival of the
general population has also increased over the same time period,
the same factors may have contributed to the improvements
observed in both contexts—namely improvements in the
standard of living and other widespread determinants of health.
This study has quantified the cumulative successional effect of a
series of improvements in the care of people with CF,
improvements in survival in excess of that observed for the
general population. It is important to consider reasons why
survival of those with CF in the US is better than that in England
& Wales, and importantly how the currently static sex difference
of those with CF may be remedied.
Until now, no therapy had been available which corrected
the molecular defect [4,26] and disease specific factors such asseverity of CFTR dysfunction may not be significantly
associated with long term survival [27]. However, the first
therapy to potentiate CFTR has just completed phase 3 trials,
seems to be highly effective [28] and to date has been
introduced in the UK and US. Long term studies will be
required to examine the survival advantage that this, and other
innovative interventions, may confer.5. Conclusion
Overall, the improvement in survival witnessed among those
with CF in absolute terms, in those countries studied, is
considerable and supports the assertion that a median survival
in excess of 50 years for those born in 2000 should be expected
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